Interleukin Genetics announced it will shut down and liquidate its assets pending shareholder approval in August.
Interleukin is the creator of PerioPredict, a test that produces genetic data that can lower a patient's systematic inflammatory burden to reduce the risk of periodontitis and other chronic diseases.
The company has about $480,000 in cash and owes about $5.6 million, with an additional $245,000 in additional expenses as part of the liquidation process. Multiple officers and directors have resigned, and Barry Kallander from KallanderGroup is currently serving as Interleukin's president, director, secretary, and treasurer to oversee the process of delisting and deregulation.
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
